1. Home
  2. NMFC vs ALLO Comparison

NMFC vs ALLO Comparison

Compare NMFC & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Mountain Finance Corporation

NMFC

New Mountain Finance Corporation

HOLD

Current Price

$7.16

Market Cap

745.2M

Sector

Finance

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$2.06

Market Cap

707.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMFC
ALLO
Founded
2010
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
745.2M
707.6M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
NMFC
ALLO
Price
$7.16
$2.06
Analyst Decision
Hold
Strong Buy
Analyst Count
4
15
Target Price
$8.63
$8.35
AVG Volume (30 Days)
480.0K
6.9M
Earning Date
05-04-2026
05-07-2026
Dividend Yield
15.27%
N/A
EPS Growth
N/A
34.09
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$142,416.42
P/E Ratio
$12.51
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.29
$0.99
52 Week High
$10.90
$4.46

Technical Indicators

Market Signals
Indicator
NMFC
ALLO
Relative Strength Index (RSI) 26.88 52.42
Support Level N/A $1.85
Resistance Level $8.17 $2.36
Average True Range (ATR) 0.19 0.13
MACD -0.07 0.02
Stochastic Oscillator 4.28 61.78

Price Performance

Historical Comparison
NMFC
ALLO

About NMFC New Mountain Finance Corporation

New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Share on Social Networks: